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Abstract
Background: Patients with multiple serrated polyps are at an increased risk for developing colorectal cancer (CRC). Recent
reports have linked cigarette smoking with the subset of CRC that develops from serrated polyps. The aim of this work
therefore was to investigate the association between smoking and the risk of CRC in high-risk genetics clinic patients
presenting with multiple serrated polyps.
Methods and Findings: We identified 151 Caucasian individuals with multiple serrated polyps including at least 5 outside the
rectum, and classified patients into non-smokers, current or former smokers at the time of initial diagnosis of polyposis. Cases
were individuals with multiple serrated polyps who presented with CRC. Controls were individuals with multiple serrated polyps
and no CRC. Multivariate logistic regression was performed to estimate associations between smoking and CRC with adjustment
for ageatfirst presentation, sex and co-existing traditional adenomas, a feature thathas been consistently linked with CRC riskin
patients with multiple serrated polyps. CRC was present in 56 (37%) individuals at presentation. Patients with at least one
adenoma were 4 times more likely to present with CRC compared with patients without adenomas (OR=4.09; 95%CI 1.27 to
13.14; P=0.02). For females, the odds of CRC decreased by 90% in current smokers as compared to never smokers (OR=0.10;
95%CI 0.02 to 0.47; P=0.004) after adjusting for age and adenomas. For males, there was no relationship between current
smoking and CRC. There was no statistical evidence of an association between former smoking and CRC for both sexes.
Conclusion: A decreased odds for CRC was identified in females with multiple serrated polyps who currently smoke,
independent of age and the presence of a traditional adenoma. Investigations into the biological basis for these observations
could lead to non-smoking-related therapies being developed to decrease the risk of CRC and colectomy in these patients.
Citation: Buchanan DD, Sweet K, Drini M, Jenkins MA, Win AK, et al. (2010) Risk Factors for Colorectal Cancer in Patients with Multiple Serrated Polyps: A Cross-
Sectional Case Series from Genetics Clinics. PLoS ONE 5(7): e11636. doi:10.1371/journal.pone.0011636
Editor: Syed A. Aziz, Health Canada, Canada
Received May 30, 2010; Accepted June 15, 2010; Published July 16, 2010
Copyright:  2010 Buchanan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Cancer Council Queensland, the Hicks Foundation in Victoria, and the National Cancer Institute through
1R01CA123010 (Genetics of Serrated Neoplasia) and RFA # CA-95-011 through cooperative agreements with the Australasian Colorectal Cancer Family Registry
(U01 CA097735). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Joanne.Young@qimr.edu.au
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11636Introduction
Familial non-syndromic colorectal cancer (CRC) constitutes one
of the most difficult and diverse patient groups encountered in a
genetics clinic, with no apparent germline mutation, an often-
indeterminant mode of inheritance, and questions arising as to
how to manage the probands, and how to identify which family
members are also at risk for CRC. One such condition is
hyperplastic polyposis syndrome (HPS), a colorectal polyposis of
unknown etiology characterized by the development of multiple
serrated polyps in the large intestine. Efforts to define the clinical
boundary of HPS have been hampered by heterogeneity of
phenotype, with a vast array of polyp numbers, sizes [1],
histological subtypes [2], and varying distributions in the colon
leading to a set of recognition criteria which are necessarily
stringent but which may exclude a significant number of high-risk
cases [3]. The clinical significance of HPS is that it is associated
with an increased personal and familial risk of CRC [4,5,6,7], and
extra-colonic cancers in the wider family setting [8].
Some 10 years ago, Rashid et al suggested that there are at least
two phenotypic subtypes of HPS. The first demonstrates numerous
hyperplastic polyps which may or may not be large, and such
patients have also been described in series by Williams et al [9]
and Ferrandez et al [10]. An alternative phenotype of HPS
demonstrates fewer polyps than that described above however
includes a diversity of polyp types including common hyperplastic
polyps, serrated adenomas, sessile serrated adenomas, traditional
adenomas, and polyps with mixed elements [1,11]. This second
phenotype of HPS is reported to be more likely to have polyps
with diameters exceeding 1cm, dysplastic changes, to involve the
proximal colon and to be associated with the presence of CRC [6].
Despite this, estimation of CRC risk in individual patients with
HPS remains problematical [12,13]. That there are at least two
forms of HPS has been also suggested by others [14]. The reasons
for this phenotypic dichotomy are currently unknown but may
involve genetic backgrounds and environmental modifiers.
One environmental modifier may be cigarette smoking. The
relationship between serrated neoplasia and smoking has been
examined in a number of population-based studies [15], and
evidence for an association has emerged for both precursor and
malignant lesions in the serrated pathway [16,17,18,19,20,21].
Multiple independent studies have shown an identical pattern of
higher risk estimates for serrated (hyperplastic) polyps than for
adenomas [16,17,19] in long-term and current smokers. The
highest risks of all were observed when both adenomas and
serrated polyps were present [16,17,19]. In a meta-analysis of risk
factors for serrated polyps, both common and advanced lesions
were significantly associated with current cigarette smoking [22].
Consistent with this, several large population-based studies have
demonstrated that the CRC subset bearing the molecular
signature of serrated neoplasia, namely somatic BRAF mutation,
CpG Island Methylator Phenotype (CIMP) and microsatellite
instability (MSI) has the highest association with smoking [23]
[18,20]. Given these findings, the authors have explored the effects
of cigarette smoking on phenotype and risk of CRC in a large
series of high-risk patients with multiple serrated polyps attending
genetics clinics. This study presented an opportunity to determine
whether cigarette smoking contributed to the increased risk of
CRC in these patients.
Methods
This cross-sectional study comprised 151 Caucasian patients
with multiple serrated polyps (with at least 5 occurring outside the
rectum) recruited from genetics clinics in Australia and New
Zealand (n=139) and North America (n=12) regardless of family
history of polyps and cancer. This was done in order to target
high-risk patients more likely to be predisposed to serrated polyps
whilst simultaneously limiting the chances of recruiting patients
with common late-onset distal serrated polyps. Forty-one patients
from Australia were participants in the Colon Cancer Family
Registry (Colon CFR) [24], 39 were from the Royal Melbourne
Hospital Hyperplastic Polyposis Study [25], and the balance of
participants were enrolled in the Genetics of Serrated Neoplasia
(GSN) study (http://gsn.qimr.edu.au/index.html) through Cancer
Care Ontario, Ohio State University Medical Center, the
Combined Genetics Clinics of Australia and the Familial GI
Cancer Registry of New Zealand. Thirty-six patients from
Australia, and 8 from North America have been reported
previously [25,26]. Patients gave written informed consent to
participate in research and the study was approved by the HREC
of Queensland Institute of Medical Research under the Genetics
of Serrated Neoplasia Project (QIMR HREC Protocol P912).
Definitions
The use of the term serrated polyp in this report encompasses any
polyp with serrated glandular architecture [27], and includes
hyperplastic or metaplastic polyps, serrated adenoma, sessile
serrated adenoma and mixed polyps. Minimum reported polyp
count was obtainable from patient records in 120 individuals and
in the remaining 31 individuals, polyposis was described as
numerous (n=2), prolific (n=1) or multiple suggesting hyperplas-
tic polyposis and prompting referral to a genetics clinic (n=28).
Polyposis was categorised into two groups where polyp count was
known; moderate (5–79 polyps) and dense ($80 polyps) [28], and
into those fulfilling WHO HPS criterion 3 (.30 polyps throughout
the colon) and those with polyp counts between 5 and 30 [3].
Cigarette smoking status of patients at the time of initial diagnosis with
polyposis was categorised into 3 groups; never, former and current
smokers. Cases were individuals with multiple serrated polyps
who presented with at least one CRC at the time of initial
diagnosis with polyposis. Controls were individuals with multiple
serrated polyps who had not developed CRC at the time of initial
diagnosis with polyposis. Index patients were those who presented
independent of other family members, and screening cases were
diagnosed subsequently to an index case in their respective
families.
Polyps and Cancers
Pathology review of polyps was undertaken by a specialist
gastrointestinal pathologist (NIW). Twenty-eight CRC were
available for analysis and underwent a BRAF V600E somatic
mutation test as follows. The somatic T.A mutation at nucleotide
1799 causing the V600E mutation in the BRAF gene was
determined using a fluorescent allele specific PCR assay. Briefly,
20–50ng of DNA, extracted from formalin-fixed paraffin-embed-
ded tumour tissue, was amplified in a 25ml reaction containing
100nM each of allele specific primers tagged with differing
fluorophores (Mutant Primer (F1): 6-Fam-59-CAGTGAT-
TTTGGTCTAGCTTCAGA-39 Wild Type Primer (F2): NED -
59- TGATTTTGGTCTAGCTACAGT-39 and a common re-
verse primer (Reverse Primer (REV): 59-CTCAATTCTTAC-
CATCCACAAAATG-39), together with 2.5units of Taq poly-
merase (Eppendorf), 16buffer and 200mM of dNTPs. The cycling
conditions consisted of an initial denaturation of 95uC for 2mins
followed by 35 cycles of 94uC for 30sec, 59uC for 30sec and 65uC
for 30sec then a final extension of 65uC for 10mins. After
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HiDi formamide and ROX Genescan 500 size marker (Applied
Biosystems, Foster City, CA). The mutant allele (A1799) primer
generated a PCR product of 97bp, 3bp larger than the wildtype
PCR product after separation on an ABI 3100 genetic analyser.
GeneMarker (SoftGenetics) software was used to identify the
different size and fluorescent allele PCR products. Positive and
negative controls were run in each experiment and 10% of
samples were replicated with 100% concordance.
Statistical Analysis
Logistic regressions were performed to estimate odds ratios
(ORs) and 95% confidence intervals (95% CIs) for the associations
between predictor variables and CRC. Patients with missing data
were excluded from the analyses. To estimate the independent
effect of cigarette smoking on the risk of CRC, we used
multivariable logistic regression models adjusting for potential
confounders including age at diagnosis, sex and presence of
traditional adenomas. We also tested for interactions between sex
and cigarette smoking status in association with CRC. The
association between smoking and CRC was estimated separately
for males and females. All regression models were compared using
the Bayesian Information Criterion [29,30].
All statistical tests were two-sided and P-value ,0.05 was
considered as a significant level of statistical evidence to reject the
null hypothesis. All statistical analyses were done using Stata 10.0
[31].
Results
In this analysis, a total of 151 patients diagnosed with multiple
serrated polyps were recruited from Australia (n=89), New
Zealand (n=50), Ohio, USA (n=11) and Canada (n=1). CRC
was diagnosed in 57 (38%) individuals at presentation. The
frequency of patients from Australasia presenting with CRC (37%)
was not different significantly from that of North America (42%)
(P=0.8). Baseline characteristics for the study patients are shown
in Table 1.
Of all participants, 33% (30/90) of female and 43% (26/61) of
male patients presented with at least one CRC. Mean age at
diagnosis of polyposis cases with CRC was 52 (standard deviation,
SD 15) years ranging from 18 to 85 years while mean age at
diagnosis of polyposis in controls (no CRC) was 46 (SD 15) years
ranging from 16 to 76 years (P=0.033). Where site was known,
62% (33/53) of CRC occurred in the proximal colon (P,0.001).
Proximal cancer was less frequent in patients under 50 (8/21 or
38%) compared to patients aged 50 and over (25/32 or 78%)
(OR=0.17; 95%CI 0.05 to 0.58; P=0.005). There was no
significant difference between the sexes with respect to the location
of the CRC (P=0.48). Eleven of twenty eight CRC cases (39%)
tested positive for somatic BRAF mutation and all 11 were located
in the proximal colon. Patients presenting with CRC had
significantly higher reported polyp counts (58, SD 55) than did
those with no CRC (32, SD 24) (P=0.002).
A total of 140 patients had at least one polyp reported as an
adenoma. Of these, 49 (45%) individuals had CRC. Patients with
colorectal adenomas were four times more likely to be diagnosed
with CRC compared to patients without adenomas (OR=4.09;
95%CI 1.27 to 13.14; P=0.02) after adjusting for age, sex and
smoking status (Table 2). Patients with dense polyposis ($80
polyps) had 5 times increased odds of CRC compared to those
with moderate polyposis (5–79 polyps) (OR=4.31; 95%CI 1.74 to
16.24; P=0.003). Similarly patients who met WHO HPS criterion
3 were three times more likely to have CRC compared to those
who did not (OR=2.63; 95%CI 1.15 to 6.00; P=0.02). We found
no statistical evidence for increased odds of CRC in patients with
advanced serrated polyps (most of which were non-dysplastic
sessile serrated adenomas) compared to those without (adjusted
OR=1.15; 95%CI 0.47 to 2.78; P=0.76). All associations (ORs)
were adjusted for age, sex and smoking status (not shown in the
tables).
Of patients diagnosed with CRC, 26 (47%) patients had no
history of smoking while 19 (34%) and 10 (20%) patients were
former and current smokers respectively. Odds of CRC for former
smokers was not statistically different compared to never smokers
Table 1. Baseline characteristics of participants in the study.
Cases
(n=56)
Controls
(n=95)
n/N (%) n/N (%)
Recruitment Site
Australia 39/89 (44) 50/89 (56)
New Zealand 12/50 (24) 38/50 (76)
Ohio, USA 4/11 (36) 7/11 (64)
Canada 1/1 (100) 0/1(0)
Sex
female 30/90 (33) 60/90 (67)
Age (years)
mean (SD) 51.6 (15.0) 46.2 (14.6)
Adenoma
No 4/27 (15) 23/27 (85)
Yes 48/109 (44) 61/109 (56)
Unknown status 4/15 (27) 11/15 (73)
Advanced serrated polyps
No 15/41 (37) 26/41 (63)
Yes 22/58 (38) 36/58 (62)
Unknown status 19/52 (37) 33/542(63)
Minimum number of polyps reported
mean (SD) 58 (55) 32 (24)
Polyposis
moderate (5–79) 32/105 (30) 73/105 (70)
dense ($80) 13/19 (68) 6/19 (32)
Unknown status 11/27 (41) 16/27 (59)
WHO Criterion 3
No (5–30 hyperplastic polyps) 19/65 (29) 46/65 (71)
Yes (more than 30 hyperplastic polyps) 26/57 (46) 31/57 (54)
Unknown status 11/29 (38) 18/29 (62)
Cigarette smoking
Never 26/61 (43) 35/61 (57)
Former 19/39 (49) 20/39 (51)
Current 10/49 (20) 39/49 (80)
Unknown status 1/2 (50) 1/2 (50)
Female Current Smokers 2/29 (7) 27/29 (93)
Male Current Smokers 8/20 (40) 12/20 (60)
aincludes dysplastic serrated polyps.
SD=Standard Deviation.
Cases (n=56) presented with CRC and polyposis, controls (n=95) with
polyposis only.
doi:10.1371/journal.pone.0011636.t001
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sex and adenomas. In addition, there was no statistical difference
in the average pack-year exposure between patients with and
without CRC (mean pack-years 13.9 vs 14; P=0.95). We found no
significant differences in polyp counts between current smokers
and former smokers for either males (mean polyp count 49 vs 41;
P=0.46) or females (41 vs 45; P=0.74), and between current
smokers and never smokers for either males (mean polyp count 49
vs 38; P=0.36) or females (41 vs 37; P=0.84).
Current smokers were at 65% decreased odds of CRC
compared with never smokers (OR=0.35; 95%CI 0.14 to 0.88;
P=0.03) after adjusting for age, sex and adenomas. For females,
the odds of CRC decreased by 90% in current smokers compared
to never smokers (OR=0.10; 95%CI 0.02 to 0.47; P=0.004) after
adjusting for age and adenomas. For males, there was no statistical
evidence for an association between current smoking and CRC
(Table 3). The association between current smoking and CRC for
male and female HPS cases was statistically different (Interaction
between current smoking and sex; P=0.02). Of all patients in the
study, 113/151 (75%) were index patients (those representing the
initial diagnosis in each family). When the analysis was confined to
index patients, the same pattern of decreased risk in females was
observed (OR=0.11; 95%CI 0.02 to 0.62; P=0.01). A schematic
diagram of the relationship between smoking status at diagnosis
and presenting with a CRC is shown in Figure 1, and details of
all female patients in the study are given in Table S1.
Discussion
In this cross-sectional series of high-risk patients with multiple
serrated polyps, we have shown that the risk of CRC is increased
in the presence of a synchronous adenoma, and decreased in
females who are current smokers, regardless of age. In contrast, a
positive association between smoking and colorectal neoplasia has
been consistently reported. Multiple primary reports and meta-
analyses have demonstrated that long term and current exposure
to cigarette smoke is significantly associated with both colorectal
cancer and its precursor lesions [16,18,19,20,21,22,32,33,34,
35,36,37,38,39,40,41,42,43,44,45,46,47,48]. The evidence regard-
ing precursor lesions is particularly strong. In a meta-analysis of 42
independent studies, smoking was significantly associated with
adenomatous polyps with an OR of 2.14 (95%CI 1.86–2.46). Risk
estimates were higher in studies where the control population had
undergone colonoscopy [34], thus supporting an earlier hypothesis
proposed by Terry and Neugut [49] that controls need to be
screened in order that a more accurate risk estimate be obtained.
When serrated polyps are examined, higher risk estimates than for
adenomas are obtained, and higher again are the risk estimates
from patients with both serrated polyps and adenomas [16,17,19].
When the association between smoking and colorectal cancer is
analysed, risk estimates are decreased compared to those obtained
when studying polyps, a phenomenon known as the smoking paradox.
Two reasons for this have been proposed. Firstly that the effect of
smoking on polyps may be greatest in small lesions with little
malignant potential, and secondly that a longer latency period
than the duration of many cohort studies may be required for
smoking to exert its effects [34]. Whilst both of these reasons are
likely to contribute to the smoking paradox, recent work on
molecular sub-typing has demonstrated that smoking is signifi-
cantly associated with the subset of colorectal cancers which
harbor a somatic mutation in BRAF [18], and this may also
contribute to the apparent dilution effect of smoking on colorectal
cancer as BRAF-mutated cancers comprise only 10% overall.
Where CRC were linked to somatic BRAF mutation, the risk was
associated with long-term smoking [18].
Despite this evidence, international health-governing bodies
such as the office of the US Surgeon General and the International
Agency for Research on Cancer (IARC) have deemed this
evidence insufficient to establish causality [32]. The major reason
for this is that the results may be confounded by factors associated
with both smoking and colorectal cancer such as physical activity
[50], alcohol consumption [51], and diet [52]. A recent report
however addressed both multiple risk factors and long duration of
smoking in studying a large cohort of patients where the median
duration of smoking was 44 years. The results confirmed that long-
term smoking presented the highest risk for colorectal cancer, even
after adjusting for multiple covariates known to affect risk [32].
Given the consistent findings from multiple reports that current
smoking increases the risk of serrated polyps, and the significant
association between smoking and colorectal cancer which develops
via the serrated pathway, we studied a group of high-risk patients
predisposed to develop multiple serrated polyps with a view to
Table 2. Association between smoking, adenoma, sex, age
and CRC in patients presenting with multiple serrated polyps.
Univariate Multivariate*
OR (95%CI) P-value OR (95%CI) P-value
Cigarette
smoking
Never 1.00 (Referent) 1.00 (Referent)
Former 1.28 (0.57 to 2.87) 0.550 0.71 (0.29 to 1.77) 0.463
Current 0.35 (0.15 to 0.82) 0.015 0.35 (0.14 to 0.88) 0.026
Never 1.00 (Referent) 1.00 (Referent)
Ever
# 0.67 (0.34 to 1.32) 0.247 0.50 (0.24 to 1.07) 0.075
Adenoma
No 1.00 (Referent) 1.00 (Referent)
Yes 4.52 (1.47 to 13.97) 0.009 4.09 (1.27 to 13.14) 0.018
Sex
Female 1.00 (Referent) 1.00 (Referent)
Male 1.49 (0.76 to 2.90) 0.247 1.57 (0.73 to 3.36) 0.245
Age (year) 1.03 (1.00 to 1.05) 0.033 1.01 (0.98 to 1.04) 0.510
*adjusted for other variables in the table.
#both former or current smokers.
doi:10.1371/journal.pone.0011636.t002
Table 3. Association between cigarette smoking and CRC in
multiple serrated polyp patients stratified by sex.
Females Males
Cigarette
smoking OR (95%CI)* P-value OR (95%CI)* P-value
Never 1.00 (Referent) 1.00 (Referent)
Former 0.85 (0.25 to 2.86) 0.795 1.00 (0.23 to 4.42) 0.996
Current 0.10 (0.02 to 0.47) 0.004 1.24 (0.26 to 5.86) 0.784
Never 1.00 (Referent) 1.00 (Referent)
Ever
# 0.31 (0.11 to 0.86) 0.025 1.18 (0.33 to 4.20) 0.799
*adjusted for age and adenomas.
#both former or current smokers.
doi:10.1371/journal.pone.0011636.t003
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present in this group of patients. Our results suggest that in
patients predisposed to developing multiple serrated polyps, there
is no significant association between smoking and an increased risk
of presentation with CRC. In a recently-reported analysis of risk
factors for serrated polyps, current smokers showed significant
increases in risk for both common and advanced serrated polyps
particularly in the distal colon [22]. In our study, CRC were more
likely to be proximal, suggesting that if the effect of smoking in
patients with multiple serrated polyps is to increase the likelihood
of left sided polyps, then our findings that smoking overall has no
significant effect on CRC development is consistent with this, as
left colon serrated polyps are less likely to undergo malignant
conversion. Of interest, a previously reported association with
distal CRC was confirmed in our study in patients aged under 50
at presentation [25,28,53].
An unexpected finding of our study was that current smoking in
females reduced the risk of presenting with CRC when compared
to never smokers. This result remained significant after adjusting
for both age at presentation and adenomas, as patients with a
CRC were older at presentation than patients without a malignant
lesion, as well as the finding of an increased risk of CRC conferred
by at least one traditional adenoma. The two female patients in
our study who were currently smoking and who presented with
CRC were later-onset, and were among the long-term smokers
(.40 years) as well as those with the highest polyp counts (122 and
129 respectively, with pan-colonic polyposis but interestingly
concentrated in the recto-sigmoid). In a very recent publication,
Walker and colleagues presented a series of 32 patients,
predominantly female, with hyperplastic polyposis where 9
currently smoking female patients were described. Of note, three
of these 9 patients had CRC and all 3 had recto-sigmoid polyp
counts .50 [54]. Therefore it is likely that the females with
multiple serrated polyps whose disease is more proximally located
are the targets of this observed effect. In addition, the effect on
female current smokers, though significant, was not complete, and
suggests only a subset with a particular genetic background or who
are within a dose-response window, are responding to a
component of cigarette smoke, and this fraction will vary among
patient cohorts. Polyp counts were significantly higher in patients
with CRC in our series, however variances were large thus
suggesting an overlapping distribution of cancer risk, and highlight-
ing the complex nature of this condition. The most important risk
factor for CRC remained the presence of a co-existing
adenomatous lesion [6,28,55], the nature of which is a current
area of investigation [56]. Of the 4 patients with CRC in whom no
traditional adenomas were reported, one demonstrated multiple
serrated adenomas (dysplastic serrated polyps). The confirmation
that the presence of dysplasia in individuals with multiple serrated
polyps is a risk factor for developing CRC will signal to clinicians
the need for increased vigilance if continuing colonoscopic
surveillance in these individuals and may trigger a discussion
regarding surgery if all polyps cannot be removed.
Patients with HPS as currently defined are at a significantly
increased risk of presenting with CRC, and are likely to represent
a subset of the population with a particular genetic background
[57]. Two large studies of 77 and 126 patients respectively, suggest
that the risk of CRC in HPS is approximately 30–40% [28,58],
and coupled with a high background of somatic BRAF mutation
(30–40% of CRC arising in HPS have a somatic BRAF mutation)
[59], such an elevated risk may simply serve to overwhelm any
effect of smoking on BRAF-mutated CRC. In the current report,
we found no evidence that current smoking was more likely to be
associated with a BRAF-mutated CRC. Of interest, a recent
publication has shown that the BRAF-smoking-CRC axis is
essentially confined to males [60].
The apparent decrease in CRC risk for currently smoking
females is consistent with a biological mechanism akin to that
observed in patients with ulcerative colitis which may be operating
in a subset of female patients with multiple serrated polyps. The
anti-inflammatory effects of smoking in ulcerative colitis are
anecdotally well known, and the risk to females of CRC in
ulcerative colitis is significantly decreased with respect to males
[61]. The results reported here suggest that inflammatory
processes may be responsible for neoplastic progression in serrated
neoplasia predisposition in a subset of female patients. A risk factor
study for serrated polyps has demonstrated that aspirin use
decreased the risk of advanced proximal polyps, lending indirect
Figure 1. Schematic diagram of all female patients in the study with CRC and smoking status, showing the decreased odds of
presenting with CRC in those currently smoking.
doi:10.1371/journal.pone.0011636.g001
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factors related to body mass index (BMI), or hormonal factors, as
are seen in the protective effects of smoking on endometrial cancer
may be confounding the results reported here. Since no BMI or
hormonal data were available for these patients at the time of
writing, it is not possible to test this hypothesis. Of interest,
decreased risks from current smoking for ASPs have been reported
previously from a series of serrated polyp patients with no co-
existing CRC or adenomas [62], and this work alludes to possible
overlapping mechanisms with the findings of our report. Though
cases in that report were not partitioned by sex, another previous
report has shown that advanced serrated polyps are more likely to
be present in females [63].
The results of our study suggest that current smoking neither
accounts for, nor exacerbates, the high risk of CRC in patients
predisposed to multiple serrated polyps. Further, in females with
multiple serrated polyps, current smoking appears to be associated
with a decreased risk of presenting with CRC. Due to the limited
numbers in our analysis, our findings may be due to chance. The
results of our study may also be influenced by ascertainment status of
the patients, but when we reanalyzed our data using only index
patients, the results remained significant. Three-quarters of our
patients represented the first presentation in their respective families,
and 70% of thesehad no affected relatives with CRC so were referred
to the genetics service on the basis of having polyposis. A further effect
on the outcomes reported here is that confounders including diet,
obesity, physical activity, hormonal status and alcohol intake, may
have influenced the results, and further larger studies will be needed
to confirm our findings both in high-risk clinics and in the population.
Our findings are unlikely to be broadly applicable to sporadic CRC
c a s e sa sp a t i e n t sw i t hm u l t i p l es e r r a t e dp o l y p sf r o mg e n e t i c sc l i n i c s
are likely to have a particular genetic background, however, there
may be some overlapping effects [62]. The direct effects of sex
hormones alone can be ruled out by the number of females, many of
whom are below the age of menopause, who were former or never
smokers and who have presented with CRC. The increased
proportion of patients with numerous serrated polyps who are
current smokers has been noted previously [28,54], and this
observation requires further investigation to determine whether
cigarette smoking enhances the phenotype [28], thus bringing it to
clinical attention, or is associated with symptom relief in patients with
a high polyp burden who therefore continue to smoke.
Importantly, investigations into the biological mechanism for
our observation of decreased risk of CRC in females may lead to a
CRC-preventive modality for female patients with serrated polyps
independent of cigarette smoking and its attendant health risks, and
may ultimately lead to a desirable reduction in the incidence of
colectomy in the management of high-risk female patients with
multiple serrated polyps. In addition, increased surveillance may
be required in females when smoking cessation occurs to
counteract any potential rebound effect. If this biological
mechanism is an anti-inflammatory process, alternative therapies
to nicotine could potentially be established in the treatment
regimen of female patients with multiple serrated polyps.
Supporting Information
Table S1 Details for all female participants with multiple
serrated polyps. FH CRC=family history of CRC; ASP=
advanced serrated polyp; AD=adenomas; CRC=presented with
CRC at initial diagnosis; y=yes, n=no, u=unknown
Found at: doi:10.1371/journal.pone.0011636.s001 (0.21 MB
DOC)
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